Who this is for
Medical information
See new evidence on your products and their competitors before the inquiries about it arrive, and keep standard responses current.
Publications and medical communications
Know when your own papers are cited, when competitors publish, and where the gaps in the literature are opening up.
Drug safety and pharmacovigilance
Get new publications screened for safety relevance each week and receive potential cases through a logged route, alongside the process you already run.
Medical strategy and HEOR
Follow the evidence that shapes treatment decisions and payer arguments without running a separate set of searches for it.
What changes for the team
How the work tends to look today, and how it looks once MedIntel is in place.
How MedIntel helps
Searches that keep running
Define what matters once: your products, their competitors, the indications, the mechanisms, the safety topics, the authors. The searches then run continuously, and new publications are picked up as they appear. When a product gets a new indication or a competitor enters the market, the scope is changed in one place and every team benefits.
Screening that separates what matters from what doesn't
Each new publication is assessed for what it means to each team: a safety finding, new efficacy data, a comparison with a competitor, a citation of your own work, a change in how the condition is treated. Teams see the items that concern them, grouped and summarized, instead of an undifferentiated list.
Safety findings routed in one click
When a publication contains a possible adverse event, anyone who sees it can send it to drug safety with the source attached. The hand-off is recorded with who sent it and when. Your safety team keeps its own process and decides what to do with each case. MedIntel makes sure the case reaches them.
Read once, used by everyone
A paper that matters to medical information, publications and drug safety is screened once and shown to all three. The time saved is not only in searching. It is in not having three people read and summarize the same article in three different inboxes.
A record of what was reviewed
Monitoring is only as good as the evidence that it happened. Each review leaves a record of what was screened, when and with what outcome, which makes internal audits and inspections a matter of showing the history rather than reconstructing it.
An example
One paper, three teams
A case series is published describing an unexpected adverse reaction in patients taking a drug in your class, including two patients on your product.
On the morning it appears, MedIntel flags it for drug safety as potentially reportable, and the safety lead sees it with the source attached. The routing is logged. The same paper appears in the medical information workspace, flagged as likely to generate questions, so the team can prepare a response before the first inquiry arrives. Publications sees it too, because it touches an evidence gap the team has been tracking.
Nobody had to forward anything, and three teams did not each spend an hour on the same article.
Common questions
If yours isn't here, ask us directly.
What is literature monitoring in pharma?
It is the routine work of following newly published research on a company's products, their competitors and the conditions they treat. Medical teams use it to stay current and answer questions. Drug safety teams use it to find reports of adverse events that may need to be assessed and reported.
How often are new publications picked up?
Continuously. Items on a watchlist trigger an alert the day they appear, and everything else is summarized in a weekly review for each team.
Does it replace our pharmacovigilance literature process?
It is designed to sit alongside it. Your safety team keeps its validated process and decides what to do with each case. MedIntel makes sure potential cases found anywhere in the organization reach that team quickly, with a record of the hand-off.
Does it follow conference abstracts as well as journals?
Yes. Abstracts and posters are followed alongside journal publications, which matters in fast-moving therapy areas where data appears at congresses months before it is published in full.
Who decides what counts as relevant?
Your teams do. You set the products, indications, competitors and topics to follow and what each team needs to see. The set-up can be changed at any time as your portfolio changes.
How quickly can we start?
Within a few weeks. Most of the work is agreeing the scope of the searches and who receives what. Teams usually find the scope they agree on is broader than any one of them was covering before.
Further reading
Glossary: Evidence gap, Medical information, Pharmacovigilance, Publication planning, Real-world evidence, Share of voice